Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol. 2019;5(5):285–307.

Article  PubMed  PubMed Central  Google Scholar 

Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. Int J Womens Dermatol. 2020;6(5):349–56.

Article  PubMed  PubMed Central  Google Scholar 

Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl. 1):31–9.

Article  PubMed  PubMed Central  Google Scholar 

Aizman L, Nelson K, Sparks AD, Friedman AJ. The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol. 2020;19(5):477–82.

Article  PubMed  Google Scholar 

Can G, Demir M, Erol O, Aydiner A. A comparison of men and women’s experiences of chemotherapy-induced alopecia. Eur J Oncol Nurs. 2013;17(3):255–60.

Article  PubMed  Google Scholar 

Barbu MA, Nitipir C, Voiosu T, Giurcaneanu C. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study. Rom J Intern Med. 2018;56(2):96–101.

PubMed  Google Scholar 

Tsutsui K, Kikuchi K, Nozawa K, Takashima A, Tsuchiyama K, Namikawa K, et al. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: a multicenter, phase II trial. J Dermatol. 2021;48(7):1077–80.

Article  CAS  PubMed  Google Scholar 

McGarvey EL, Leon-Verdin M, Baum LD, Bloomfield K, Brenin DR, Koopman C, et al. An evaluation of a computer-imaging program to prepare women for chemotherapy-related alopecia. Psychooncology. 2010;19(7):756–66.

Article  PubMed  PubMed Central  Google Scholar 

Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17(4):317–28.

Article  PubMed  Google Scholar 

Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724–8.

Article  PubMed  PubMed Central  Google Scholar 

Choi EK, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103–10.

Article  PubMed  Google Scholar 

Jo SJ, Shin H, Jo S, Kwon O, Myung SK. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol. 2015;40(3):260–70.

Article  CAS  PubMed  Google Scholar 

Bitto FF, Konig A, Phan-Brehm T, Vallbracht T, Koch JG, Schinkothe T, et al. EVA-Scalp: evaluation of patient satisfaction with a scalp cooling device to prevent chemotherapy-induced alopecia in breast cancer patients. Breast Care (Basel). 2020;15(2):171–7.

Article  PubMed  Google Scholar 

Marks DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, Isakoff SJ, Lacouture ME, et al. The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review. Breast Cancer Res Treat. 2019;175(2):267–76.

Article  PubMed  Google Scholar 

Kim JW, Cha Y, Kim SJ, Han SW, Oh DY, Lee SH, et al. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. Support Care Cancer. 2012;20(2):395–403.

Article  PubMed  Google Scholar 

Urakawa R, Tarutani M, Kubota K, Uejima E. Hand foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer. 2019;10(20):4846–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat. 2018;50(4):1186–93.

Article  PubMed  Google Scholar 

Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–33.

Article  PubMed  Google Scholar 

Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011;16(10):1469–78.

Article  PubMed  PubMed Central  Google Scholar 

Fabbrocini G, Cristaudo A, Ionescu MA, Panariello L, Robert G, Pellicano M, et al. Topical non-occlusive polymers in hand-foot syndrome. G Ital Dermatol Venereol. 2018;153(2):165–71.

PubMed  Google Scholar 

Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, et al. Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: a preplanned analysis of the ReDOS trial. Oncologist. 2021;26(7):610–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robijns J, Lodewijckx J, Claes M, Tuts L, Lenaerts M, Wessels T, et al. Evaluation of a novel skin care product for the management of chemotherapy-related dermatologic toxicities: a quasi-experimental study. Eur J Oncol Nurs. 2023;63: 102278.

Article  PubMed  Google Scholar 

Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, et al. Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes. 2010;8:40.

Article  PubMed  PubMed Central  Google Scholar 

Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME. A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Support Care Cancer. 2018;26(4):1169–79.

Article  PubMed  Google Scholar 

Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park). 2007;21(11 Suppl. 5):34–6.

PubMed  Google Scholar 

Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: survivors’ perspectives. Support Care Cancer. 2010;18(11):1461–8.

Article  PubMed  Google Scholar 

Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, et al. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol. 2019;25(29):4007–18.

Article  PubMed  PubMed Central  Google Scholar 

Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, et al. Targeted therapy-induced facial skin toxicities: impact on quality of life in cancer patients. Asia Pac J Oncol Nurs. 2018;5(2):172–7.

Article  PubMed  PubMed Central  Google Scholar 

Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, et al. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016;24(2):513–21.

Article  PubMed  Google Scholar 

Chan JC, Lee YH, Liu CY, Shih HH, Tsay PK, Tang WR. A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy. J Nurs Res. 2019;27(6): e51.

Article  PubMed  Google Scholar 

Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916–23.

Article  PubMed  Google Scholar 

Suh Oh HJ, Florez Menendez A, Sacristan Santos V, Fernandez Ribeiro F, Vilanova-Trillo L, Constenla Figueiras M, et al. Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study. Drugs Context. 2020;9.

De Tursi M, Zilli M, Carella C, Auriemma M, Lisco MN, Di Nicola M, et al. Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. Onco Targets Ther. 2017;10:3007–15.

Article  PubMed  PubMed Central  Google Scholar 

Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol. 2012;11(11):e61–5.

PubMed  Google Scholar 

Komatsu H, Yagasaki K, Hirata K, Hamamoto Y. Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: a qualitative study. Eur J Oncol Nurs. 2019;38:65–9.

Article  PubMed  Google Scholar 

Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol. 2016;27(9):1712–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847–53.

Article  CAS  PubMed  Google Scholar 

Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–7.

Article  CAS  PubMed